Mavorixafor NEW
| Price | $64 | $93 | $155 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Mavorixafor | CAS No.: 558447-26-0 |
| Purity: 98.56% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Mavorixafor |
| Description | Mavorixafor (AMD-070) is an effective and selective antagonist of CXCR4, with an IC50 value of 13 nM against CXCR4 125I-SDF binding. Mavorixafor inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells (IC50 = 1 nM) and PBMCs (IC50 = 9 nM). |
| Cell Research | Cells are seeded on a 96-well plate at 5 × 10^3 cells/well in DMEM containing 10% FCS. Twenty-four hours later, the cells are treated with or without 2 μM AMD3100 or 6.6 μM AMD-070. After 24 or 48 h, the number of cells is quantified by an assay using MTT [2]. |
| Animal Research | BALB/c nude mice are maintained under pathogen-free conditions. The experiments are initiated when the mice are 8 weeks of age. Briefly, the cells are inoculated into the blood vessels of nude mice (1× 10^6). These mice are sacrificed at day 49. The presence or absence of distant metastases is confirmed by hematoxylin and eosin (H&E) staining. For experimental chemotherapy, the mice are treated by the daily oral administration of 0.2 mL of saline for a vehicle or the same volume of AMD-070 (2 mg/kg) [2]. |
| In vitro | Mavorixafor (6.6 μM) significantly decreases the anchorage-dependent growth, migration, and matrigel invasion of the B88-SDF-1 cells [1]. Mavorixafor shows no effect on other chemokine receptors (CCR1, CCR2b, CCR4, CCR5, CXCR1, and CXCR2) [2]. |
| In vivo | AMD-070 (2 mg/kg, p.o.) markedly decreases the quantity of metastatic lung nodules in mice and reduces human Alu DNA expression without causing weight loss [1]. |
| Storage | store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 44 mg/mL (125.9 mM) H2O : 7 mg/mL (20.03 mM), Heating is recommended. DMSO : 17 mg/mL (48.64 mM) |
| Keywords | CXCR | Mavorixafor | Human immunodeficiency virus | AMD070 | HIV | inhibit | CXC chemokine receptors | AMD 070 | Inhibitor |
| Inhibitors Related | AZD8309 | rac-NBI-74330 | Delmetacin | Tannic acid | Artemotil | CXCR2-IN-1 | LIT927 | Reparixin | Plerixafor octahydrochloride | Nicotinamide N-oxide | Plerixafor | CXCL-CXCR1/2-IN-1 |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1.00/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2020-01-02 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY